OLFML2B: A Conserved Protein with Potential Clinical Applications
OLFML2B: A Conserved Protein with Potential Clinical Applications
Olfactomedin-like protein 2B (ISOform 2) (OLFML2B) is a protein that is expressed in various tissues throughout the body, including the brain, heart, kidneys, and liver. It is a member of the Olfactomedin gene family, which is characterized by the presence of a unique C-terminal region that is composed of a conserved domain that is similar to the N-terminal region of Olfactomedin-like proteins.
OLFML2B is a 21-kDa protein that is expressed in the brain, heart, and kidneys, and it is also found in various other tissues, including the liver, pancreas, and salivary glands. It is characterized by a highly conserved N-terminal region that is composed of a unique domain that is similar to the N-terminal region of Olfactomedin-like proteins. This domain is known as the \"olfactored\" domain, and it is characterized by the presence of a conserved basic amino acid sequence that is similar to the N-terminal region of Olfactomedin-like proteins.
The olfactored domain is responsible for the unique biochemical and cellular functions of OLFML2B. This domain is involved in the regulation of various cellular processes, including cell adhesion, migration, and survival. It is also involved in the regulation of cellular signaling pathways, including the TGF-β pathway, which is a well-known regulator of cell growth, differentiation, and survival.
OLFML2B is also characterized by a unique C-terminal region that is responsible for its unique biochemical and cellular functions. This region is involved in the regulation of various cellular processes, including cell adhesion, migration, and survival. It is also involved in the regulation of cellular signaling pathways, including the TGF-β pathway, which is a well-known regulator of cell growth, differentiation, and survival.
The potential clinical applications of OLFML2B as a drug target or biomarker are vast and varied. OLFML2B has been shown to play a role in the regulation of various cellular processes, including cell adhesion, migration, and survival. As a result, OLFML2B has been shown to be a potential drug target for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.
In addition to its potential clinical applications, OLFML2B also has the potential to serve as a biomarker for a variety of diseases. The conserved N-terminal and C-terminal regions of OLFML2B make it a unique and stable protein that can be used as a protein biomarker for a variety of diseases. For example, the conserved N-terminal and C-terminal regions of OLFML2B have been shown to be highly stable and to be resistant to various forms of degradation, which makes them an attractive candidate for use as a protein biomarker.
In conclusion, OLFML2B is a unique and conserved protein that is expressed in various tissues throughout the body. It is characterized by a highly conserved N-terminal region that is involved in the regulation of various cellular processes, including cell adhesion, migration, and survival. The potential clinical applications of OLFML2B as a drug target or biomarker are vast and varied, and the study of OLFML2B is an important area of research that has the potential to lead to new and improved treatments for a variety of diseases.
Protein Name: Olfactomedin Like 2B
The "OLFML2B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OLFML2B comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
OLFML3 | OLIG1 | OLIG2 | OLIG3 | Oligosaccharyltransferase complex | OLMALINC | OLR1 | OMA1 | OMD | OMG | OMP | Oncostatin-M Receptor | ONECUT1 | ONECUT2 | ONECUT3 | OOEP | OOSP1 | OOSP2 | OPA1 | OPA1-AS1 | OPA3 | OPALIN | OPCML | OPHN1 | Opioid receptor | OPLAH | OPN1LW | OPN1MW | OPN1MW3 | OPN1SW | OPN3 | OPN4 | OPN5 | OPRD1 | OPRK1 | OPRL1 | OPRM1 | OPRPN | OPTC | OPTN | OR10A2 | OR10A3 | OR10A4 | OR10A5 | OR10A6 | OR10A7 | OR10AA1P | OR10AB1P | OR10AC1 | OR10AD1 | OR10AF1P | OR10AG1 | OR10AK1P | OR10C1 | OR10D1P | OR10D3 | OR10D4P | OR10G2 | OR10G3 | OR10G4 | OR10G7 | OR10G8 | OR10G9 | OR10H1 | OR10H2 | OR10H3 | OR10H4 | OR10H5 | OR10J1 | OR10J2P | OR10J3 | OR10J5 | OR10K1 | OR10K2 | OR10P1 | OR10Q1 | OR10R2 | OR10S1 | OR10T2 | OR10V1 | OR10W1 | OR10X1 | OR10Z1 | OR11A1 | OR11G2 | OR11H1 | OR11H12 | OR11H13P | OR11H2 | OR11H5P | OR11H6 | OR11H7 | OR11J2P | OR11J5P | OR11K2P | OR11L1 | OR11M1P | OR12D2 | OR12D3 | OR13A1
